People with rapidly progressing idiopathic pulmonary fibrosis (IPF) have significantly higher levels of circulating cell-free DNA (ccfDNA) than those with slower disease progression and healthy people, a small study shows. In addition, ccfDNA levels, which have been suggested to contribute to IPF, were found to be associated with changes in…
In commemoration of the International Quality of Life Month happening in January, the Pulmonary Fibrosis Foundation (PFF) is calling attention to the educational resources it offers, which are designed to support and improve the lives of people with pulmonary fibrosis (PF). “This January, start the New Year on…
The first patient has been enrolled in a pivotal Phase 2b trial investigating the safety and effectiveness of Horizon Therapeutics’ oral medicine candidate HZN-825 in people with idiopathic pulmonary fibrosis (IPF). The trial (NCT05032066) aims to enroll approximately 360 people with IPF, ages 18–80, whose disease symptoms…
Fibrosis or scarring in the lungs may blunt the ability of the body’s immune cells to fight off an infection in idiopathic pulmonary fibrosis (IPF), a study in mice found. Researchers observed that when isolated from a fibrotic lung, macrophages — a type of white blood cells that engulfs…
Mesenchymal stromal cells (MSCs) lessened lung scarring by reducing idiopathic pulmonary fibrosis (IPF)-related aging of lung cells that play a key role in tissue repair, according to a study in a mouse model of IPF. Notably, these benefits were associated with a normalization of the levels of molecules involved…
Anti-fibrotic medications, such as Esbriet (pirfenidone) and Ofev (nintedanib), are not cost-effective treatments for idiopathic pulmonary fibrosis (IPF) in the U.S. due to their high prices, even though they remain the only effective therapies, according to a recent study. The study, “Cost-effectiveness of the anti-fibrotics for…
Injuries to the lung from diseases like idiopathic pulmonary fibrosis (IPF) can trigger an abnormal cell response that affects lung cell repair and is associated with excessive tissue scarring, a study showed. Scientists noted that further studies are needed to determine whether this process is reversible, which may lead…
Patients with idiopathic pulmonary fibrosis (IPF) with chronic cough who are being treated with the investigational oral medication NP-120 (ifenprodil) in a small clinical trial tended to experience a reduction in coughing, according to the therapy’s developer Algernon Pharmaceuticals. The company is funding an open-label Phase 2…
Cudetaxestat (BLD-0409), an experimental medication for idiopathic pulmonary fibrosis (IPF) from Blade Therapeutics, was well-tolerated among healthy volunteers when given in combination with other IPF treatments — specifically nintedanib and pirfenidone — in a Phase 1 study. “These findings provide confidence in the potential to safely co-administer cudetaxestat…
Enrollment has been completed for INTEGRIS-IPF, a Phase 2a trial testing PLN-74809, an experimental oral anti-fibrotic therapy, in people with idiopathic pulmonary fibrosis (IPF). Pliant Therapeutics, the company developing PLN-74809 and sponsoring the trial, said it is expecting top-line results to become available midway through the year. The…
Get regular updates to your inbox.
